Items seized from aesthetic clinic over intent to supply concerns
A Medicines Enforcement Officer from the Department of Health (DH) has told the trial of an aesthetics nurse that a search warrant was used to seize a number of items from her clinic because of concerns of intent to supply.
Nichola Hawes, 49, is on trial for alleged fraud and selling or supplying medicines, including weight-loss drugs and Botox, without proper prescriptions.
She runs Nichola Hawes Aesthetic Clinic on Groomsport Road in Bangor, and faces 31 charges, including fraud by false representation.
Warren McKee, a Medicines Enforcement Officer with the DH told the jury of six men and six women at Downpatrick Crown Court, that on the 28 November 2022, he seized a number of medicinal items from the clinic.
This was done under the concern that they were not going to be used for the person that they were prescribed to.
Following the search, in February 2023, Ms Hawes took part in an interview with the Medicines Regulatory Group - accompanied by her solicitor - and this interview was relayed to the court.
The court heard Ms Hawes was asked during the meeting if it was the case that she was creating a stock of prescription only medicines - so that people can walk in off the street and be treated there and then in her clinic - to which Nichola Hawes replied: 'No comment.'
During the meeting Ms Hawes said the majority of her clients came to her for Botox and that she had a well-established business.
She said if her clients did not go through with orders such as Botox the order was destroyed.
She also added that a new patient requesting Botox would always have to wait at least one day before receiving their treatment.
Ms Hawes was asked if she could explain why a prescription had been written for a woman called Lauren Caproni, if Ms Caproni did not receive any treatment after filling in an online questionnaire for the self-administering weight-loss drug, Ozempic.
She was also asked why would she prescribe something for somebody if they had not asked for it or received it – and questioned as to why she had a back log of Ozempic in her clinic.
To each of these questions and several others, it was relayed to the court that Ms Hawes had answered no comment.
The jury heard that Ms Hawes said she had made one mistake in relation to client Jordan Cairns - when she accidently put another client's prescription under her name, but she added that this was an administrative error.
Ms Hawes said she had full records and notes, was widely known and respected and at no point had any patient been at risk.
The jury also heard from a second Medicines Enforcement Officer, Jacqueline Pyper.
She told the court she had visited the home of a former client of Ms Hawes, Louise Abott, who had previously ordered two weight loss pens from Ms Hawes.
Ms Abott showed Ms Pyper her previous orders, which came in a box with someone else's name on it.
She also confirmed to Ms Pyper that she did not ask Ms Hawes to order a third pen for her.
The trial continues.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Weight-Loss Medications Less Effective for People in the 'Real World,' New Study Finds
A new study analyzed patients who used GLP-1 medications in a real-world setting Researchers found that participants lost less weight compared to use in clinical trials They believe discontinuation rates are due to high out-of-pocket costs, issues with insurance coverage, side effects and supply shortagesWeight-loss medications like Ozempic and Mounjaro are not as effective in a 'real-world' setting, according to a new study. The study — published June 10 in the Obesity Journal — analyzed nearly 8,000 patients who were classified as having severe obesity. Between 2021 and 2023, they were treated with semaglutide or tirzepatide, injectable GLP-1 medications, in a real-world setting. GLP-1 is short for glucagon-like peptide-1 receptor agonists, which work in the brain to impact satiety. Semaglutide is sold under brand names Ozempic and Wegovy, and tirzepatide is sold under brand names Mounjaro and Zepbound. In a follow-up study, which ended in December 2024, researchers grouped patients who discontinued their obesity medications into those who discontinued early (within 3 months) and late (within 3-12 months). Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. is now available in the Apple App Store! Download it now for the most binge-worthy celeb content, exclusive video clips, astrology updates and more! They found that more than 20% of patients discontinued their medications early and 32% discontinued their medications late. Additionally, more than 80% of patients were on lower maintenance dosages of their medications. After a year of treatment, the average weight loss was 3.6% for those who discontinued their treatment early, compared to 6.8% for those who discontinued their treatment late. Those who continued treatment lost about 12% of their body weight. During clinical trials for the GLP-1s, patients lost about 15% to 20% of their body weight. 'Our findings about the real-world use patterns of these medications and associated clinical outcomes could inform the decisions of healthcare providers and their patients on the role of treatment discontinuation and maintenance dosage in achieving clinically meaningful weight reductions,' Dr. Hamlet Gasoyan, Cleveland Clinic researcher and lead author of the study, said in a statement. The study notes that discontinuation rates during real-world use were higher than those in a clinical trial setting due to high out-of-pocket costs, issues with insurance coverage, side effects and supply shortages. Read the original article on People
Yahoo
4 hours ago
- Yahoo
Inside the Investigation: Texas Governor vetoes Botox patient safety bill
AUSTIN (KXAN) — On the last day of the 2025 Texas legislative session, Gov. Greg Abbott vetoed a bill aimed at enhancing safety and transparency for Texans getting Botox. This week on Inside the Investigation, Investigative Reporter Arezow Doost explains why, at the last minute, the state's top leader rejected the measure. Backroom Botox is a 'wild west' in Texas 'Botox party' bill heads to governor On the final day of the session, Gov. Abbott vetoed the Botox patient safety bill filed after a KXAN investigation Join KXAN Investigative Reporter Kelly Wiley every Friday at 10:30 a.m. on KXAN+, YouTube, Facebook, or for a recap of the latest reporting from the KXAN Investigates team. You can also listen to KXAN's investigative podcast, highlighting some of our award-winning team's latest reports exposing corruption, safety concerns, and system failures across Texas. We also feature audio versions of our weekly 'Inside the Investigation' discussion with the journalists working on those stories. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
5 hours ago
- Yahoo
Novo Nordisk ramps up obesity fight, advances amycretin to Phase III
Novo Nordisk is progressing both subcutaneous and oral versions of amycretin into Phase III trials for patients with obesity and who are overweight. Following a positive end-of-Phase II meeting, Novo Nordisk shared that regulatory authorities have approved the therapy to proceed. The company plans to initiate the trial in adults who are overweight or with obesity in Q1 2026. Executive vice president for development at Novo Nordisk, Martin Lange said: 'We are very pleased that the feedback from regulatory authorities has allowed us to take subcutaneous and oral amycretin in weight management to Phase III. We are excited about the amycretin molecule, and this marks an important step forward. We look forward to sharing more information on the design of the Phase III programme.' In a Phase Ib/IIa study (NCT06064006), amycretin, a glucagon-like peptide-1 (GLP-1) and amylin receptor co-agonist, showed weight-loss outcomes of up to 22% in 36 weeks. This was higher than seen by the company's blockbuster therapy Wegovy (semaglutide), which demonstrated a body weight change of 14% at week 36 in a Phase II study. The Phase Ia/IIb study investigated three doses of once-weekly subcutaneous amycretin in 125 patients who are overweight or with obesity. The primary endpoint was treatment-emergent adverse events (TEAEs), with Novo Nordisk reporting that the most common events were gastrointestinal, and the majority were mild to moderate in severity. If successful in a Phase III trial, GlobalData anticipates that amycretin will receive approval for adults with overweight or obesity in Q4 2030 in the US, followed by approval in the EU in Q1 2031. GlobalData is the parent company of Clinical Trials Arena. Novo Nordisk has signed a $812m partnership with Deep Apple Therapeutics to access novel compounds, not GLP-1RAs, for obesity and other diseases. As well as this, the company has also listed two new studies for CagriSema, another candidate in its pipeline. The company recently announced underwhelming data from a Phase III trial, which, while meeting its primary endpoint, fell short of the 25% weight loss promise. Following all these updates, Novo Nordisk's share price has now increased, making it the most valuable company in Europe once again. It has a market cap of $359.28bn compared to German software company SAP at $359bn. Novo Nordisk's flagship semaglutide, marketed as Wegovy in weight loss and Ozempic in type 2 diabetes, is forecast to make $49bn in sales in 2030, according to GlobalData. Its main competitor, Eli Lilly's tirzepatide, marketed as Zepbound in weight loss and Mounjaro in type 2 diabetes, is projected to reach sales of $60.8bn. Lilly's drug proved to have higher efficacy than Novo Nordisk's in a head-to-head study between the pair. "Novo Nordisk ramps up obesity fight, advances amycretin to Phase III" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data